US OptionsDetailed Quotes

MOR240719C17500

Watchlist

0.90
0.000.00%

15min DelayClose Jul 18 14:32 ET

0.00High0.00Low

MorphoSys Stock Discussion

Meltyy

May 22 02:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics(IOVA.US)$ Phase 2
$Supernus Pharmaceuticals(SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US)$ Phase 2a
$MorphoSys(MOR.US)$ Phase 2
$Nuvation Bio(NUVB.US)$ Phase 2
$ALX Oncology(ALXO.US)$ Phase 2
$BioXcel Therapeutics(BTAI.US)$ Phase 2
$Purple Biotech(PPBT.US)$ Phase 2
$Arcus Biosciences(RCUS.US)$ Phase 2
$Medicenna Therapeutics(MDNAF.US)$ Phase 2b
$Affimed NV(AFMD.US)$ Phase 2
$Barinthus Biotherapeutics(BRNS.US)$ Phase 2b...

Meltyy

May 12 21:23

🎯 Ph 3 readouts in Q2 2024...

$United Therapeutics(UTHR.US)$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US)$ Phase 3
$Liquidia(LQDA.US)$ Phase 3
$United Therapeutics(UTHR.US)$ Phase 3
$MorphoSys(MOR.US)$ Phase 3
$Immunocore(IMCR.US)$ Phase 3
$Crinetics(CRNX.US)$ Phase 3
$UroGen Pharma Ltd(URGN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$AstraZeneca(AZN.US)$ Phase 3
$Capricor Therapeutics(CAPR.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3...

Trytosaveabit

Feb 6 13:00

WOW! Anyone else read this yet! Grrrrr! What’s true! Hehehe

$MorphoSys(MOR.US)$ MorphoSys Spokesperson Says "This Story Is Factually Wrong" In An Emailed Statement To Bloomberg News, In Response To STAT News' Adam Feuerstein Article Entitled, "Why Novartis Is Going To Walk Away From Its Acquisition"
Benzinga· 5 mins ago
Why Novartis is going to walk from its acquisition of MorphoSys (statnews.com)
Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not c...

Moomoo AI

Feb 6 03:32

Palantir's Q4 commercial business performance was 'bombastic, baller, incomprehensibly good', according to CEO Alex Karp. Coherent sees 'improving demand trends', expecting 'ongoing sequential improvement in revenue growth'. Chegg's Q1 guidance disappointed investors. NXP Semiconductors' Q4 results surpassed expectations. Novartis' acquisition of MorphoSys is viewed positively.